-
Mashup Score: 3Session to explore GLP-1, GIP RAs in mental disorders, addiction, and more - ADA Meeting News - 13 day(s) ago
Roger S. McIntyre, MD, FRCPC, and other investigators will outline unanticipated effects of using incretin receptor agonists outside of the clinical impact on weight loss and metabolic disorders.
Source: www.adameetingnews.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 383rd Scientific Sessions | American Diabetes Association - 13 day(s) ago
There are companies that are claiming to offer registration services for ADA’s Scientific Sessions, which are not affiliated with ADA and do not offer any servi ces on our behalf. Registration should only be accessed from the ADA website. If you do not see this logo on the website then they are not our official provider! If you were unable to attend the American Diabetes Association 83rd Scientific Sessions, it’s not too late to access over 800 presentations highlighting the most exciting science in
Source: professional.diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
The 84th Scientific Sessions is seeking high-quality, innovative session proposals to enhance next year's event. This is your chance to contribute to the scientific program and showcase the latest advancements. Submit your proposals by August 14, 2023! https://t.co/yIQNrh28L6 https://t.co/sWI4Igt5eI
-
-
Mashup Score: 90Time to reframe the disease staging system for type 1 diabetes - 13 day(s) ago
In 2015, introduction of a disease staging system offered a framework for benchmarking progression to clinical type 1 diabetes. This model, based on islet autoantibodies (stage 1) and dysglycaemia (stage 2) before type 1 diabetes diagnosis (stage 3), has facilitated screening and identification of people at risk. Yet, there are many limitations to this model as the stages combine a very heterogeneous group of individuals; do not have high specificity for type 1 diabetes; can occur without persistence (ie, reversion to an earlier risk stage); and exclude age and other influential risk factors.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New in the December Issue: Time to reframe the disease staging system for type 1 #diabetes https://t.co/2l3BfhYCKz #T1D https://t.co/ysLkEO7lsr
-
-
Mashup Score: 31Continuous glucose sensor accuracy: beyond the headline metric - 13 day(s) ago
The promotion of continuous glucose monitoring (CGM) to standard of care for type 1 diabetes and insulin-treated type 2 diabetes reflects a robust and wide evidence base for the technology’s effectiveness supported by real-world efficacy data. Multiple CGM devices are available worldwide and are marketed, in part, based on accuracy data. In this Viewpoint, we argue that accuracy metrics are no longer a point of difference between CGM devices as almost all exceed an acceptable threshold. We also argue that domains of standardisation, clinical outcomes, and sustainability should now be given primacy as CGM devices seek to be implemented for new indications.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Continuous glucose sensor accuracy: beyond the headline metric https://t.co/2c9KZpqtEq #CGM #diabetes #T1D #T2D
-
-
Mashup Score: 8EASD e-Learning Newsflash: Highlights from Day 2 of the 85th ADA Scientific Sessions - 13 day(s) ago
Prof. Simon Heller, University of Sheffield Prof. Richard Oram, University of Exeter Prof. Tina Vilsb ø ll, University of Copenhagen
Source: easd-elearning.euCategories: General Medicine News, EndocrinologyTweet-
EASD e-Learning Newsflash Day 2 #ADASciSessions: 📉 @simonrheller on CGM & TBR, for assessing the risk of #hypo? 🧬🦠@RAOram on #genes, #viruses as the potential causes of #T1D. 💊 @TinaVilsbon the next-gen, non-peptide #GLP1RA and new phase 3 data. 📺 https://t.co/gct5aCMH0a https://t.co/BlBOzThriS
-
-
Mashup Score: 42024 Recognized Abstracts | American Diabetes Association - 13 day(s) ago
LYNN ANG, YI YUAN HUANG, CATHERINE MARTIN, KARA R. MIZOKAMI-STOUT, YU KUEI LIN, ALEXI VASBINDER, MOUSUMI BANERJEE, SALIM HAYEK, EVA L. FELDMAN, RODICA BUSUI, Ann Arbor, MI ADAM SEAL, STEVEN K. MALIN, ANDREW SCHAFFNER, MICHAEL R. HUBBARD, SARAH K. KEADLE, HANNAH BRUNNER-GAYDOS, ALIA A. ORTIZ, JANE E. NAKAMURA, CLARA MCMAHON, RACHEL BARNETT, ANITA H. KELLEHER, KELLY A. BENNION, SUZANNE PHELAN, TODD HAGOBIAN, San Luis Obispo, CA, New Brunswick, NJ, Gilbert, AZ, San, CA, Seattle, WA, San Francisco, CA JURAJ
Source: professional.diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
The Health Disparities Committee’s Top 10 Recommended Abstracts recognizes abstracts that have been accepted to the #ADASciSessions. These abstracts focus on health care disparities/inequities in diabetes outcomes. For more information, visit https://t.co/bcCnMJKh0g. https://t.co/CIUuBFuJK9
-
-
Mashup Score: 2Endocrine Self-Assessment Program (ESAP) 2025 Book - 13 day(s) ago
Advance your expertise with Endocrine Self-Assessment Program (ESAP™) 2025 Book, the leading self-study program for physicians and endocrinologists. The latest edition features 120 new cases that reflect real-world challenges in endocrinology. Each question includes clinical background, patient history, and laboratory results to guide your diagnosis.
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet-
Endocrine Self-Assessment Program (ESAP) 2025 | Order our dynamic self-study tool is designed to boost your expertise and elevate the quality of care you provide to your patients. Claim up to 40 AMA PRA Category 1 Credits: https://t.co/03ogmEDWYD #endocrinology https://t.co/V8onU0H9SR
-
-
Mashup Score: 41Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions - 13 day(s) ago
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Estimating direct tissue effects versus weight loss effects of #incretin-based drugs for #obesity on various chronic conditions https://t.co/vjdHEUm5Ei #weightloss #GLP-1 receptor agonists
-
-
Mashup Score: 1
CHICAGO — The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without diabetes, researchers reported. Results of the REDEFINE 1 trial comparing cagrilintide/semaglutide (CagriSema, Novo Nordisk) with placebo in patients with overweight or obesity and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰 Once-weekly combination cagrilintide and semaglutide induced significant weight loss for adults with #obesity. Learn more about the REDEFINE trials presented at #ADA2025 ⬇️ @ADADiabetesPro #ADASciSessions @GoHealio https://t.co/onzY9WmDpe
-
-
Mashup Score: 3CagriSema Demonstrates Significant Weight Loss in Adults with Obesity | American Diabetes Association - 13 day(s) ago
Findings from two studies highlight the potential for CagriSema, a dual agonist that targets both glucose regulation and appetite control, to improve weight loss in patients with and without type 2 diabetes who have overweight or obesity.
Source: diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
PRESS RELEASE: CagriSema Demonstrates Significant Weight Loss in Adults with Obesity Details: https://t.co/Z0gFk09WxO #ADASciSessions https://t.co/I0mUasgbpE
-
#ADASciSessions Preview: @rogersmcintyre and other experts will highlight several unexpected effects of using incretin receptor agonists beyond weight loss and metabolic disorders. đź”— Read more: https://t.co/HyZTu2Yj1l https://t.co/SqfZJpeRjt